Background: A major barrier for the clinical application of genetics in hypertrophic cardiomyopathy (HCM) is a lack of data on the relation between genotype and phenotype. Aim: Discover new genetic determinants of HCM phenotype using high-throughput genotyping. Methods: Unrelated and consecutive patients (pts) were studied. Highthroughput sequencing was used to analyze 41 genes. Rare variants (vts) were tested for associations with the phenotype. Results: The cohort comprised 384 pts (46.3±15.1 years at initial evaluation, 71.4% males). Candidate sarcomere or sarcomere-associated vts were present in 240 pts (63%). Seventy-five percent were either previously published or novel loss-of-function or insilico predicted to be pathogenic. Rare vts in desmosomal and ion-channel genes were each present in 88 (23%) pts. Table 1 shows some of the significant genotype-phenotype associations. Conclusions: Genotype-phenotype relationships, some of them novel, were identified for sarcomere and related genes. Non-sarcomeric vts seem to have a phenotype-modifier effect.
Purpose: To date, clinical studies on hypertrophic cardiomyopathy (HCM) have assessed outcome irrespective of genetic background. However, the large proportion of patients with no detectable sarcomere myofilament gene mutations, possibly including phenocopies, may confound our perception of the the natural history of HCM due to sarcomeric myofilament mutations. We therefore investigated the clinical features and outcome of 250 HCM patients followed 6±3 years after genetic identification of such mutations. The impact of the implantable cardioverter-defibrillator (ICD), both in terms of appropriate intervention rates and adverse effects, was specifically assessed. Results: Overall, 16 pts (6%; incidence 1% per year) died of cardiovascular causes, including progressive heart failure (n=7), SCD (n=5), ischemic stroke (n=1) and other non cardiac diseases (n=3). Of these, 9 (5%) occurred in the subset of patents without ICD (group 1) including 3 sudden deaths; while 7 (11%) occurred among pts with ICD (group 2), of whom 3 had prior appropriate interventions. Two of the deaths in group 2 were sudden, occurring despite the device: unfortunately, neither an autopsy nor an ICD interrogation was performed in these pts, and the exact causes of death could not be ascertained. At final evaluation, 6±3 years after genetic testing, 34 pts (14%) were in NYHA class III/IV and 25 (10%) had overt LV systolic dysfunction (LVEF <50%). Survival in the two groups was comparable (p=0.15) despite more severe clinical profile and greater preva- Objective: Isolated noncompaction cardiomyopathy (NCCM) is considered a primary genetic cardiomyopathy. Smaller studies suggest that the prognosis of pts with NCCM is determined by heart failure (HF) symptoms, different arrhythmias, and thrombembolic events, ranging from asymptomatic to life threatening events. To investigate possible risk factors in this disease we analysed the data of the German NCCM registry (ALKK), which is a registry in a real life clinical setting. Methods: By January 31th, 2013 the German NCCM registry had enrolled a total of 269 pts with NCCM (180 male, age 18 to 88 years, mean age 53.8 yrs) with a mean follow up period of 28 mths. ECGs, echocardiographic and cardiac MR images were reviewed. The pts were followed in 6 mths intervals for clinical events and symptoms. The incidence of severe HF symptoms (NYHA III/IV), malignant arrhythmias (VT/VF), embolic events and deaths were analysed in respect to the factors: age, gender, LV systolic function, atrial fibrillation (AF), left bundle branch block (LBBB) and the presence of late enhancement (LE) in the MR images. Results: Age and gender showed no significant influence on the clinical events of the pts, although there were more men included. The presence of a LBBB was significantly associated with symptoms of heart failure (Odds ratio (OR) 2.54, 95%-confidence interval (CI) (1.42, 4.54)), malignant arrhythmias (OR 2.49, CI (1.23, 5.05)) and cardiac (OR 8.49, CI (2.52, 28.65) ) and all cause (OR 4.17, CI (1.61, 10.79)) death. The presence of AF was correlated with a higher risk of death for all-cause mortality (OR 4.66, CI (1.78, 12.19) ) and for cardiac deaths (OR 5.86, CI (1.88, 18.32) ). Severely depressed LV ejection fraction (EF) was a significant risk factor for deaths (OR 6.78, CI (2.18, 21 .04)), for cardiac deaths (OR 9.63, CI (2.09, 44.37)), for heart failure (OR 8.9, CI (5.05, 15.67)) and for VT/VF (OR 2.32, CI (1.18-4.55)). LE in MRI was rarely found in the pts of the registry. There was no statistic significant correlation between the presence of LE and events. The analysed risk factors showed no correlations to embolic events. Summary: In the real life clinical setting of the German NCCM registry prognosis was better than previously reported. Pts with NCCM and AF, LBBB, depressed LVEF (<35%) were at high risk for a significant clinical event. 
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